Daprodustat is a novel oral hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) designed specifically for the treatment of anemia associated with chronic kidney disease (CKD).

1、 Drug name

Common name: Daprodustat

Product Name: JESDUVROQ

2、 Indications

Used to treat anemia caused by chronic kidney disease, suitable for adult patients who have received dialysis for at least 4 months.

3、 Specifications

Specification: 1mg tablet

4、 Main components

Active ingredient: Dapuxostat

5、 Usage and dosage

Administration method: Oral once daily.

Usage: Swallow the whole tablet, do not cut, crush or chew.

Dietary requirements: Can be taken with food or on an empty stomach, not affected by iron or phosphorus binding agents.

6、 Dose adjustment

Initial dose:

Patients who have not used ESA: Determine based on hemoglobin levels (4mg for<9g/dL; 2mg for ≥ 9- ≤ 10g/dL; 1mg for>10g/dL).

Conversion from ESA to patient: Determine based on the current ESA dose (range 1-12mg).

Dose levels: 1mg, 2mg, 4mg, 6mg, 8mg, 12mg, 16mg, 24mg.

Adjustment principle:

When hemoglobin rises too quickly (2 weeks>1g/dL or 4 weeks>2g/dL), it needs to be reduced.

Hemoglobin levels greater than 11g/dL should be reduced, while levels greater than 12g/dL should be temporarily discontinued.

Adjust the dosage every 4 weeks, adjusting one dosage level at a time.

7、 Medication precautions

Omission treatment: Take the missed dose immediately when remembered. If it is already time for the next dose, skip the missed dose and do not double the dose.

8、 Medication for special populations

Liver dysfunction:

Moderate damage (Child Pugh B grade): The initial dose is halved (except for 1mg dose).

Severe damage (Child Pugh C grade): Not recommended for use.

Pregnancy: May cause fetal damage, pregnant women should avoid using it.

Breastfeeding period: It is not recommended to breastfeed during the treatment period and within one week after the last dose.

Elderly: No special dosage adjustment required.

Children: Safety and efficacy have not been determined yet.

9、 Adverse reactions

The most common adverse reactions (≥ 10%) are hypertension, thrombotic vascular events, and abdominal pain.

Other common reactions (≥ 5%): Dizziness, allergic reactions.

Serious risks: death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis.

10、 Contraindications

Patients using strong CYP2C8 inhibitors (such as gefilzil)

Uncontrolled hypertensive patients

11、 Drug interactions

Strong CYP2C8 inhibitors: Do not use in combination.

Moderate CYP2C8 inhibitor: The initial dose is halved.

CYP2C8 inducer: may reduce efficacy, hemoglobin needs to be monitored.

12、 Storage method

Stored at 20 ° C-25 ° C (68 ° F-77 ° F), allowing fluctuations within the range of 15 ° C-30 ° C (59 ° F-86 ° F).

13、 Important Warning

This drug may increase the risk of death, myocardial infarction, stroke, venous thromboembolism, and vascular access thrombosis. The target value should not be hemoglobin>11g/dL, and the lowest dose that can reduce the need for blood transfusion should be used.

Daprodustatinformation